Class Action Lawsuit Filed Against Rocket Pharmaceuticals, Inc.

Strategic Insights -

Rocket Pharmaceuticals, Inc. has been involved in a securities class action lawsuit, which alleges that the company and certain officers or directors have engaged in securities fraud or other unlawful business practices. The lawsuit concerns the company's gene therapy for Danon disease, RP-A501, and a serious adverse event that occurred in a patient participating in the Phase 2 pivotal trial. The patient passed away after an acute systemic infection, and the stock price of Rocket Pharmaceuticals fell significantly following the announcement.

Key Takeaways:

  • A class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. alleging securities fraud or other unlawful business practices.
  • The lawsuit concerns the company's gene therapy for Danon disease, RP-A501, and a serious adverse event that occurred in a patient participating in the Phase 2 pivotal trial.
  • The patient in question passed away after an acute systemic infection, and the stock price of Rocket Pharmaceuticals fell $3.94 per share, or 62.84%, to close at $2.33 per share on May 27, 2025.
  • The lawsuit was filed on behalf of investors who purchased or otherwise acquired Rocket securities during the Class Period.
  • Pomerantz LLP, a law firm with expertise in class action lawsuits, is leading the case.
  • The firm has recovered numerous multimillion-dollar damages awards on behalf of class members in the past.

Statistics:

  • The stock price of Rocket Pharmaceuticals fell $3.94 per share, or 62.84%, to close at $2.33 per share on May 27, 2025.
  • The patient in question passed away after an acute systemic infection following a serious adverse event in the Phase 2 pivotal trial of RP-A501.
  • The lawsuit was filed on behalf of investors who purchased or otherwise acquired Rocket securities during the Class Period, which ended on August 11, 2025.